Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive‐disease small cell lung cancer in the elderly and patients with poor performance status

BACKGROUND: Carboplatin plus etoposide (CE) is a standard treatment for elderly patients with extensive‐disease small cell lung cancer (ED‐SCLC). However, amrubicin monotherapy (AMR) may be a feasible alternative. We compared the efficacies and safety profiles of CE and AMR for ED‐SCLC in elderly pa...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Thorac Cancer
Main Authors: Igawa, Satoshi, Shirasawa, Masayuki, Ozawa, Takahiro, Nishinarita, Noriko, Okuma, Yuriko, Ono, Taihei, Sugimoto, Ai, Kurahayashi, Shintaro, Sugita, Keisuke, Sone, Hideyuki, Fukui, Tomoya, Mitsufuji, Hisashi, Kubota, Masaru, Katagiri, Masato, Sasaki, Jiichiro, Naoki, Katsuhiko
פורמט: Artigo
שפה:Inglês
יצא לאור: John Wiley & Sons Australia, Ltd 2018
נושאים:
Original Articles
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6068456/
https://ncbi.nlm.nih.gov/pubmed/29870153
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12772
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים